Frazier Lifesciences Acquisition Corporation Stock
Stocks
NAMS
NL00150012L7
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
2026-11-06
|
5-day change | 1st Jan Change | ||
| 18.87 EUR | -0.11% |
|
-5.93% | -46.21% |
| 11-04 | NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| 11-04 | NewAmsterdam Pharma's Q3 Net Loss Narrows, Revenue Grows | MT |
| Market Cap | 2.03B 2.26B 1.85B 1.69B 3.18B 212B 3.28B 22.31B 8.9B 113B 8.48B 8.29B 358B | P/E 2026 * |
-10.3x | P/E 2027 * | -10.9x |
|---|---|---|---|---|---|
| Enterprise Value | 1.6B 1.78B 1.46B 1.33B 2.51B 167B 2.59B 17.59B 7.01B 89.28B 6.68B 6.54B 282B | EV / Sales 2026 * |
64.5x | EV / Sales 2027 * | 11.9x |
| Free-Float |
99.11% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| NAMS | End-of-day quote | |
Nasdaq
| NAMS | Delayed | |
|
CBOE
| NAMS | Real-time | |
|
Börse Stuttgart
| KH6 | Delayed | |
|
Tradegate
| KH6 | Real-time | |
|
Boerse Muenchen
| KH6 | Real-time | |
|
Deutsche Boerse AG
| KH6 | Delayed |
Last Transcript: Frazier Lifesciences Acquisition Corporation
| 1 day | -0.11% | ||
| 1 week | -5.93% | ||
| Current month | -5.93% | ||
| 1 month | -15.27% | ||
| 3 months | -31.80% | ||
| 6 months | -39.11% | ||
| Current year | -46.21% |
| 1 week | 18.5 |  | 22.26 |
| 1 month | 18.5 | | 22.29 |
| Current year | 18.5 | | 42.2 |
| 1 year | 18.5 | | 42.2 |
| 3 years | 8.64 | | 42.2 |
| 5 years | 5.63 | | 42.2 |
| 10 years | 5.63 | | 42.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Davidson
CEO | Chief Executive Officer | 69 | 2022-10-31 |
Mayur Somaiya
DFI | Director of Finance/CFO | 52 | 2023-10-22 |
John Kastelein
CTO | Chief Tech/Sci/R&D Officer | 72 | 2022-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Davidson
BRD | Director/Board Member | 69 | 2022-10-31 |
John Kastelein
BRD | Director/Board Member | 72 | 2022-10-31 |
James Topper
BRD | Director/Board Member | 64 | 2022-10-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/30/26 | Other | Chief Technology Officer | 0 | 0% | ||
| 9/30/26 | Futurum BV
| Exercice | Company | 150,738 | 0.1261% | |
| 9/14/26 | Buy | Chief Executive Officer | 10,000 | 0.0086% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.11% | -5.93% | -49.07% | +82.85% | 2.26B | |
| -4.83% | +3.51% | +53.62% | +61.75% | 69.4B | |
| +0.02% | +1.42% | +12.77% | +75.21% | 57.24B | |
| -1.34% | +3.53% | +23.22% | +101.58% | 57.62B | |
| +2.62% | +1.68% | +28.91% | +37.01% | 43.65B | |
| +5.09% | +9.89% | +22.45% | +107.48% | 44.03B | |
| +8.24% | +0.51% | +213.26% | +792.66% | 38.08B | |
| -1.86% | +11.46% | +26.67% | +61.40% | 36.31B | |
| -2.97% | -6.89% | +91.79% | +74.60% | 32.61B | |
| -2.18% | +5.68% | +36.21% | -0.69% | 25.47B | |
| Average | +0.27% | +3.45% | +45.98% | +139.39% | 40.67B | |
| Weighted average by Cap. | +0.05% | +4.22% | +51.48% | +137.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 24.76M 27.61M 22.63M 20.66M 38.92M 2.6B 40.15M 273M 109M 1.38B 104M 101M 4.37B | 123M 137M 112M 103M 193M 12.9B 200M 1.36B 541M 6.88B 515M 504M 21.73B |
| Net income | -202M -225M -184M -168M -317M -21.14B -327M -2.22B -886M -11.28B -844M -826M -35.61B | -197M -219M -180M -164M -309M -20.61B -319M -2.17B -864M -11B -823M -805M -34.72B |
| Net Debt | -429M -478M -392M -358M -674M -44.94B -695M -4.72B -1.88B -23.98B -1.79B -1.76B -75.7B | -563M -628M -515M -470M -886M -59.05B -914M -6.21B -2.47B -31.51B -2.36B -2.31B -99.47B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-06 | €18.90 | +0.05% | 1,706,194 |
| 26-11-05 | €18.89 | -9.75% | 1,560,991 |
| 26-11-04 | €20.93 | +5.18% | 1,889,342 |
| 26-11-03 | €19.90 | +1.74% | 2,071,938 |
| 26-11-02 | €19.56 | -2.49% | 2,006,297 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NAMS Stock
Select your edition
All financial news and data tailored to specific country editions
